TaqMan MGB Probes for CPV Wild-Type Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The diagnosis of CPV-2a, CPV-2b, and CPV-2c in fecal samples from dogs can be ambiguous due to false-positive results from modified-live virus replication in vaccinated dogs, leading to misdiagnosis, and existing methods are time-consuming and require multiple steps.
Innovation Solution
A method using real-time PCR assays with TaqMan probes and conjugated minor groove binder (MGB) ligands, employing specific primers and probes to discriminate between wild-type and vaccine-type nucleic acids by targeting SNPs in the VP2 gene, allowing for accurate detection and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If real-time PCR assays with TaqMan probes and MGB ligands are used to detect CPV-2a, 2b, and 2c, then detection speed and accuracy are improved, but the complexity of the assay increases
Solution Approach 1:
The patent combines multiple functions into a single probe molecule by conjugating the minor groove binder (MGB) ligand directly to the TaqMan probe. This merging of the probe and MGB components eliminates the need for separate binding steps, accelerates hybridization kinetics, and enables real-time detection while maintaining assay specificity for distinguishing wild-type from vaccine-type CPV strains.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the probe by incorporating MGB ligands with specific binding affinities and fluorescence quenching properties. This parameter change enhances the probe's stability and signal-to-noise ratio, enabling rapid and accurate detection within the real-time PCR framework without requiring complex post-amplification processing.
2Measurement precision
If traditional PCR, cloning, sequencing, and phylogenetic analysis are used to identify CPV types, then detection accuracy is improved, but time consumption increases significantly
Solution Approach 1:
The patent performs preliminary differentiation by designing TaqMan probes with MGB ligands that are specifically complementary to nucleotide variations in the VP2 gene of different CPV types (wild-type vs. vaccine-type). This preliminary action allows the assay to distinguish between CPV types directly during the amplification phase, eliminating the need for subsequent cloning, sequencing, and phylogenetic analysis steps.
Solution Approach 2:
The patent extracts and targets only the critical nucleotide variations in the VP2 gene region that differentiate CPV types. By focusing the assay on these specific genetic markers using type-specific primers and probes, the method extracts the essential diagnostic information needed for accurate classification without requiring complete genome sequencing or extensive downstream analysis.
3Ease of operation
If standard PCR methods are used without SNP-specific probes, then ease of operation is improved, but the ability to discriminate wild-type from vaccine-type strains deteriorates
Solution Approach 1:
The patent applies local quality by designing TaqMan probes with MGB ligands that are specifically complementary to nucleotide variations at particular positions in the VP2 gene of different CPV types. This localized specificity at the probe-target interaction site enables the assay to maintain operational simplicity while achieving high precision in discriminating between wild-type and vaccine-type strains through real-time fluorescence signals.
4Reliability
If modified-live virus vaccines are administered to dogs, then protection against CPV infection is improved, but false-positive detection results occur due to virus replication in the intestinal mucosa
Solution Approach 1:
The patent inverts the detection approach by designing probes that specifically target nucleotide variations present in wild-type strains but absent or different in vaccine-type strains. This inverted strategy allows the assay to distinguish between vaccinated dogs (containing vaccine virus) and infected dogs (containing wild-type virus) by detecting the presence or absence of wild-type-specific genetic markers, thereby eliminating false-positive results.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides rapid, accurate, and stable detection of CPV-2a, CPV-2b, and CPV-2c, with a limit of detection as low as 10^1 copies and high specificity, effectively distinguishing between wild-type and vaccine-type strains, reducing misdiagnosis and improving diagnostic efficiency.
Implementation Method 1
amplifying the target nucleic acid with a template-dependent polymerase
Implementation Method 2
annealing a SNP probe to the target nucleic acid to form a hybridized product
Implementation Method 3
detecting the signals generating from the hybridized product as an indicator of the presence of the target nucleic acid
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention disclose a method for detection CPV 2a, 2b, and 2c in a sample by detecting VP2 gene. The signals can be detected by both fluorescent detection system and lateral flow immunochromatographic assay. The second object of this present invention is to provide a method to discriminate the wild type from the vaccine type. The first approach to achieve this object is discriminating wild type from vaccine type by SNP 36, which could be used on both fluorescent detection system and lateral flow immunochromatographic assay. The second approach to achieve this object is discriminating wild type from vaccine type by SNP 899 and SNP 963.